Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts

Journal of Pathology

Volumn 232, Issue 1, 2014, Pages 43-56

  Lau, Tat San ^a   Chung, Tony Kwok Hung ^a   Cheung, Tak Hong ^a   Chan, Loucia Kit Ying ^a   Cheung, Leonard Wing Hong ^a   Yim, So Fan ^a   Siu, Nelson Shing Shun ^a   Lo, Kwok Wai ^b   Yu, May Mei Yung ^b   Kulbe, Hagen ^c   Balkwill, Frances R ^c   Kwong, Joseph ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

cancer associated fibroblasts; CXCL11; CXCR3; Lymphotoxin; ovarian cancer; tumour microenvironment; tumour stromal interactions

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYMPHOTOXIN; LYMPHOTOXIN BETA RECEPTOR;

ARTICLE; CANCER CELL; CANCER GRADING; CANCER GROWTH; CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; METASTASIS; MONOCULTURE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; TUMOR BIOPSY;

CANCER-ASSOCIATED FIBROBLASTS; CXCL11; CXCR3; LYMPHOTOXIN; OVARIAN CANCER; TUMOUR MICROENVIRONMENT; TUMOUR-STROMAL INTERACTIONS;

CELL LINE, TUMOR; CHEMOKINE CXCL11; COCULTURE TECHNIQUES; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HONG KONG; HUMANS; LYMPHOTOXIN BETA RECEPTOR; LYMPHOTOXIN-ALPHA; OVARIAN NEOPLASMS; RECEPTORS, CXCR3; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84890055236     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4258     Document Type: Article

References (44)

1. Kaku T, Ogawa S, Kawano Y, et al., Histological classification of ovarian cancer. Med Electron Microsc 2003; 36: 9-17.
2. Vaughan S, Coward JI, Bast RC, Jr, et al., Rethinking ovarian cancer: recommendations for improving outcomes. Nature Rev Cancer 2011; 11: 719-725.
3. Kobel M, Kalloger SE, Boyd N, et al., Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 2008; 5: e232.
4. Lawrenson K, Gayther SA,. Ovarian cancer: a clinical challenge that needs some basic answers. PLoS Med 2009; 6: e25.
5. Cubillos-Ruiz JR, Rutkowski M, Conejo-Garcia JR,. Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. Cell Cycle 2010; 9: 260-268.
6. Balkwill F., Tumour necrosis factor and cancer. Nature Rev Cancer 2009; 9: 361-371.
7. Kulbe H, Chakravarty P, Leinster DA, et al., A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 2012; 72: 66-75.
8. Kulbe H, Thompson R, Wilson JL, et al., The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007; 67: 585-592.
9. Aggarwal BB, Moffat B, Harkins RN,. Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem 1984; 259: 686-691.
10. Schneider K, Potter KG, Ware CF,. Lymphotoxin and LIGHT signaling pathways and target genes. Immunol Rev 2004; 202: 49-66.
11. Dejardin E, Droin NM, Delhase M, et al., The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002; 17: 525-535.
12. Cupedo T, Mebius RE,. Cellular interactions in lymph node development. J Immunol 2005; 174: 21-25.
13. Rehm A, Mensen A, Schradi K, et al., Cooperative function of CCR7 and lymphotoxin in the formation of a lymphoma-permissive niche within murine secondary lymphoid organs. Blood 2011; 118: 1020-1033.
14. Bjordahl RL, Steidl C, Gascoyne RD, et al., Lymphotoxin network pathways shape the tumor microenvironment. Curr Opin Immunol 2013; 25: 222-229.
15. Shin SY, Nam JS, Lim Y, et al., TNFalpha-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. J Biol Chem 2010; 285: 30731-30740.
16. Chang YH, Hsieh SL, Chen MC, et al., Lymphotoxin beta receptor induces interleukin 8 gene expression via NF-kappaB and AP-1 activation. Exp Cell Res 2002; 278: 166-174.
17. Stopfer P, Mannel DN, Hehlgans T,. Lymphotoxin-beta receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells. J Immunol 2004; 172: 7459-7465.
18. Suto H, Katakai T, Sugai M, et al., CXCL13 production by an established lymph node stromal cell line via lymphotoxin-beta receptor engagement involves the cooperation of multiple signaling pathways. Int Immunol 2009; 21: 467-476.
19. Hosokawa Y, Hosokawa I, Ozaki K, et al., TNFSF14 coordinately enhances CXCL10 and CXCL11 productions from IFN-gamma-stimulated human gingival fibroblasts. Mol Immunol 2010; 47: 666-670.
20. Wang Y, Koroleva EP, Kruglov AA, et al., Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection. Immunity 2010; 32: 403-413.
21. Mishra P, Banerjee D, Ben-Baruch A,. Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol 2011; 89: 31-39.
22. Rasanen K, Vaheri A,. Activation of fibroblasts in cancer stroma. Exp Cell Res 2010; 316: 2713-2722.
23. Balkwill FR,. The chemokine system and cancer. J Pathol 2012; 226: 148-157.
24. Robledo MM, Bartolome RA, Longo N, et al., Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001; 276: 45098-45105.
25. Kawada K, Sonoshita M, Sakashita H, et al., Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 2004; 64: 4010-4017.
26. Lo BK, Yu M, Zloty D, et al., CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol 2010; 176: 2435-2446.
27. Liu C, Luo D, Reynolds BA, et al., Chemokine receptor CXCR3 promotes growth of glioma. Carcinogenesis 2011; 32: 129-137.
28. Kawada K, Taketo MM,. Significance and mechanism of lymph node metastasis in cancer progression. Cancer Res 2011; 71: 1214-1218.
29. Dorsam RT, Gutkind JS,. G-protein-coupled receptors and cancer. Nature Rev Cancer 2007; 7: 79-94.
30. Hehlgans T, Stoelcker B, Stopfer P, et al., Lymphotoxin-beta receptor immune interaction promotes tumor growth by inducing angiogenesis. Cancer Res 2002; 62: 4034-4040.
31. Daller B, Musch W, Rohrl J, et al., Lymphotoxin-beta receptor activation by lymphotoxin-alpha(1)beta(2) and LIGHT promotes tumor growth in an NFkappaB-dependent manner. Int J Cancer 2011; 128: 1363-1370.
32. Simonin Y, Vegna S, Akkari L, et al., Lymphotoxin signaling is initiated by the viral polymerase in HCV-linked tumorigenesis. PLoS Pathog 2013; 9: e1003234.
33. Haybaeck J, Zeller N, Wolf MJ, et al., A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16: 295-308.
34. Wolf MJ, Seleznik GM, Zeller N, et al., The unexpected role of lymphotoxin beta receptor signaling in carcinogenesis: from lymphoid tissue formation to liver and prostate cancer development. Oncogene 2010; 29: 5006-5018.
35. Ammirante M, Luo JL, Grivennikov S, et al., B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464: 302-305.
36. Drier Y, Sheffer M, Domany E,. Pathway-based personalized analysis of cancer. Proc Natl Acad Sci U S A 2013; 110: 6388-6393.
37. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
38. Furuya M, Suyama T, Usui H, et al., Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol 2007; 38: 1676-1687.
39. Furuya M, Yoneyama T, Miyagi E, et al., Differential expression patterns of CXCR3 variants and corresponding CXC chemokines in clear cell ovarian cancers and endometriosis. Gynecol Oncol 2011; 122: 648-655.
40. Ehlert JE, Addison CA, Burdick MD, et al., Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol 2004; 173: 6234-6240.
41. Kleppe M, Wang T, Van Gorp T, et al., Lymph node metastasis in stages I and II ovarian cancer: a review. Gynecol Oncol 2011; 123: 610-614.
42. Browning JL,. Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease. Immunol Rev 2008; 223: 202-220.
43. Chen X, Mihalic J, Deignan J, et al., Discovery of potent and specific CXCR3 antagonists. Bioorg Med Chem Lett 2012; 22: 357-362.
44. Halon A, Materna V, Drag-Zalesinska M, et al., Estrogen receptor alpha expression in ovarian cancer predicts longer overall survival. Pathol Oncol Res 2011; 17: 511-518.